Literature DB >> 30096332

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Sergey E Borisov1, Lia D'Ambrosio2, Rosella Centis3, Simon Tiberi4, Keertan Dheda5, Jan-Willem Alffenaar6, Rohit Amale7, Evgeny Belilowski1, Judith Bruchfeld8, Barbara Canneto9, Justin Denholm10, Raquel Duarte11, Aliasgar Esmail5, Alex Filippov1, Lina Davies Forsman8, Mina Gaga12, Shashank Ganatra7, Gaida Anastasia Igorevna13, Barbara Lazaro Mastrapa14, Vinicio Manfrin15, Selene Manga16, Andrey Maryandyshev13, Gilbert Massard17, Pablo González Montaner18, Jai Mullerpattan7, Domingo Juan Palmero18, Agostina Pontarelli19, Apostolos Papavasileiou20, Emanuele Pontali21, Rodolfo Romero Leyet22, Antonio Spanevello23, Zarir Farokh Udwadia7, Pietro Viggiani19, Dina Visca3, Giovanni Sotgiu24, Giovanni Battista Migliori25.   

Abstract

OBJECTIVES: No study evaluated the contribution of adjunctive surgery in bedaquiline-treated patients. This study describes treatment outcomes and complications in a cohort of drug-resistant pulmonary tuberculosis (TB) cases treated with bedaquiline-containing regimens undergoing surgery.
METHODS: This retrospective observational study recruited patients treated for TB in 12 centres in 9 countries between January 2007 and March 2015. Patients who had surgical indications in a bedaquiline-treated programme-based cohort were selected and surgery-related information was collected. Patient characteristics and surgical indications were described together with type of operation, surgical complications, bacteriological conversion rates, and treatment outcomes. Treatment outcomes were evaluated according to the time of surgery.
RESULTS: 57 bedaquiline-exposed cases resistant to a median of 7 drugs had indication for surgery (52 retreatments; 50 extensively drug-resistant (XDR) or pre XDR-TB). Sixty percent of cases initiated bedaquiline treatment following surgery, while 36.4% underwent the bedaquiline regimen before surgery and completed it after the operation. At treatment completion 90% culture-converted with 69.1% achieving treatment success; 21.8% had unfavourable outcomes (20.0% treatment failure, 1.8% lost to follow-up), and 9.1% were still undergoing treatment.
CONCLUSIONS: The study results suggest that bedaquiline and surgery can be safely and effectively combined in selected cases with a specific indication.
Copyright © 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  TB, MDR-TB; XDR-TB, surgery; pulmonary rehabilitation

Mesh:

Substances:

Year:  2018        PMID: 30096332     DOI: 10.1016/j.jinf.2018.08.003

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  5 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

Review 2.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

3.  Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.

Authors:  Norbert Ndjeka; Jonathon R Campbell; Graeme Meintjes; Gary Maartens; H Simon Schaaf; Jennifer Hughes; Xavier Padanilam; Anja Reuter; Rodolfo Romero; Farzana Ismail; Martin Enwerem; Hannetjie Ferreira; Francesca Conradie; Kogieleum Naidoo; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2022-05-02       Impact factor: 71.421

4.  Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?

Authors:  Svetlana Velizarova; Natalia Gabrovska; Albena Spasova; Ben Marais; Elizabeth Page Harausz; Simon Tiberi; Giovanni Battista Migliori; Davide Manissero
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

5.  Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.

Authors:  Jonathon R Campbell; Dennis Falzon; Fuad Mirzayev; Ernesto Jaramillo; Giovanni Battista Migliori; Carole D Mitnick; Norbert Ndjeka; Dick Menzies
Journal:  Emerg Infect Dis       Date:  2020-03-17       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.